Daman collaborates with Janssen to provide insights into psoriatic arthritis
26 May 2022 | Thursday | News
Daman is excited to announce that they have signed an agreement with Janssen Pharmaceutica NV (Janssen) to deliver a digital health tool (mobile application) to be used in a clinical study among people living with psoriatic arthritis. Benefitting from the HealthBuddy platform, the agreement involves developing a digital health tool for use in a clinical trial, enabling Janssen to gain new insights into how patients’ everyday lives are affected by their disease.
Image Source : Public Domain
Affecting more than 5M patients in Europe and 37.5M worldwide, Psoriatic Arthritis (PsA) imposes a high burden on individuals, societies, and the healthcare sector. The collection and utilisation of Patient Reported Outcomes (PROs) is expected to enable the transition towards more holistic care, aiming to achieve a higher quality of life for patients.
With the HealthBuddy platform—using the validated concept of the RheumaBuddy app (already used by 20,000+ Rheumatoid Arthritis patients in Europe)—Janssen will be able to not only provide patients with a valuable tool, but also obtain longitudinal data-driven insights on the everyday lives of patients enrolled in their clinical trial.
“We are excited to work with a forward-looking pharmaceutical company like Janssen on implementing an innovative digital health technology in their clinical trials. This really shows the meaning of their vision of being patient-centric,” says Andreas Dam, CEO at Daman. He continues: “Studies have shown that PROs deliver better ecological validity when filled by patients outside the clinic. Here, digital health tools are the obvious choice”.
“Despite advances in treatment, there remains several unmet needs among people living with psoriatic arthritis. We are happy to see many companies in pharmaceutical industry and digital health partner up to co-create powerful solutions,” says Jan Koren, President at EUROPSO, the federation of psoriasis patients’ associations in Europe, who has taken part in the co-creation process.
With the HealthBuddy platform—using the validated concept of the RheumaBuddy app (already used by 20,000+ Rheumatoid Arthritis patients in Europe)—Janssen will be able to not only provide patients with a valuable tool, but also obtain longitudinal data-driven insights on the everyday lives of patients enrolled in their clinical trial.
“We are excited to work with a forward-looking pharmaceutical company like Janssen on implementing an innovative digital health technology in their clinical trials. This really shows the meaning of their vision of being patient-centric,” says Andreas Dam, CEO at Daman. He continues: “Studies have shown that PROs deliver better ecological validity when filled by patients outside the clinic. Here, digital health tools are the obvious choice”.
“Despite advances in treatment, there remains several unmet needs among people living with psoriatic arthritis. We are happy to see many companies in pharmaceutical industry and digital health partner up to co-create powerful solutions,” says Jan Koren, President at EUROPSO, the federation of psoriasis patients’ associations in Europe, who has taken part in the co-creation process.
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
